Side effects of the distal gastrointestinal tract after NSAID use are common and more frequent than previously recognized. Increased @entity33 and @entity32 are often silent but appear after NSAID treatment with most dual COX inhibitors. Other clinical manifestations include: @entity417 , occult @entity190 , @entity8884 , protein-loss, @entity4628 , @entity294 , @entity9645 and strictures due to @entity66 . More common complications are @entity360 and perforation, which represent at least one third of all @entity344 observed with NSAID use. Studies with selective @entity2247 inhibitors have shown that, in the short term, these agents do not increase @entity33 or induce @entity417 due to @entity548 and that, when compared to dual COX inhibitors, lower @entity344 may be reduced by 50%. In order to minimize the impact of these side effects, it is important to increase the current standards of suspicion by physicians who treat these @entity1 , since drug discontinuation may further reduce damage, and clinical experience with agents that may prevent or treat distal tract damage is very limited. From this perspective, selective @entity2247 inhibitors may be the drugs of choice in the high-risk @entity1 that needs NSAIDs. Another important area of uncertainty is the impact of NSAID use in @entity1 with @entity29 . Data from different animal models of @entity29 suggest that inhibition of both @entity9859 and @entity2247 derived prostaglandins affects the severity of the @entity32 . However, current epidemiological and clinical data are contradictory. Since many @entity1 .

Clinical implications of XXXX and/or @entity2247 inhibition for the distal gastrointestinal tract.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity32 :: ('MESH:D007249', 'Disease') :: ['mucosal inflammation'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity8884 :: ('MESH:D008286', 'Disease') :: ['malabsorption'] @entity4628 :: ('MESH:D007077', 'Disease') :: ['ileal dysfunction'] @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss'] @entity9645 :: ('MESH:D019226', 'Disease') :: ['mucosal ulceration'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucosal permeability'] @entity66 :: ('MESH:D004194', 'Disease') :: ['diaphragm disease'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal complications'] @entity548 :: ('MESH:D006470', 'Disease') :: ['occult bleeding'] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'inflammatory bowel diseases'] @entity9859 :: ('4512', 'Gene') :: ['COX-1'] @entity2247 :: ('4513', 'Gene') :: ['COX-2'] @entity360 :: ('MESH:D006471', 'Disease') :: ['lower gastrointestinal bleeding']
@entity9859 :: (4512,Gene) :: ['COX-1']
